"Bertilimumab is a fully human, IgG4-type monoclonal antibody (mAb) that blocks the activity of a protein called eotaxin-1 that plays an important role in inflammation in multiple clinical indications.
Eotaxin-1 causes eosinophils (a type of white blood cell involved in inflammation and allergy) to migrate towards sites of inflammation where they become activated and release substances that result in tissue damage and enhance inflammation. By blocking the effects of eotaxin-1 on eosinophil function, Bertilimumab is a promising clinical stage candidate for a variety of inflammatory conditions, including Ulcerative Colitis, Crohn’s disease, Severe Asthma and Bullous Pemphigoid."
Don't we have the WI contract for tralokinumab and dupilumab from AstraZenneca / Sanofi respectively with an indication of Severe Asthma?
ALSO
"Bullous pemphigoid is an acute or chronic autoimmune skin disease, involving the formation of blisters, more appropriately known as bullae, at the space between the skin layers epidermis and dermis. It is classified as a type II hypersensitivity reaction, with the formation of anti-hemidesmosome antibodies."
